Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial readout, as global demand for the technology increases. The company ...
Six-year follow-up from a trial comparing surgery with TAVR in low-risk patients showed no difference in major events, but ...
SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...
Emboline expects that its technology designed to reduce stroke risk during structural heart procedures will launch in the US and Europe later this year.
WASHINGTON, DC — New European registry data on transcatheter aortic-valve replacement (TAVR) in patients at lower surgical risk than those studied in the pivotal randomized trials offers the ...
Both Edwards and JenaValve are currently developing transcatheter aortic valve replacement devices to treat patients with aortic regurgitation (“AR”). According to the Complaint, over 8 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results